Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer

Urologic Clinics of North America

Volumn 43, Issue 1, 2016, Pages 77-86

  Jones, Robert T ^a,b   Felsenstein, Kenneth M ^a,b   Theodorescu, Dan ^a,b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; Clinical trials; Immunotherapy; Molecular subtype; Personalized medicine; Pharmacogenomics; Precision medicine; Predictive biomarker

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN P53; TUMOR MARKER; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

BLADDER CANCER; BREAST CANCER; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DISEASE MARKER; DNA REPAIR; DNA SEQUENCE; HUMAN; LUNG CANCER; MEDICAL DECISION MAKING; MOLECULARLY TARGETED THERAPY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; TREATMENT RESPONSE; GENETICS; IMMUNOTHERAPY; NEOADJUVANT THERAPY; PHARMACOGENETICS; PREDICTIVE VALUE; URINARY BLADDER NEOPLASMS;

BIOMARKERS, TUMOR; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; PHARMACOGENETICS; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; URINARY BLADDER NEOPLASMS;

EID: 84952911963     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2015.08.007     Document Type: Review

References (72)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Howlader N, Noone AM, Krapcho M, et al, editors. SEER cancer statistics review, 1975-2011. Bethesda (MD): National Cancer Institute.
3. Svatek R.S., Hollenbeck B.K., Holmäng S., et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014, 66(2):253-262.
4. Pasin E., Josephson D.Y., Mitra A.P., et al. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 2008, 10(1):31-43.
5. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349(9):859-866.
6. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18(17):3068-3077.
7. Vale C.L. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48(2):202-206.
8. Sternberg C.N., Bellmunt J., Sonpavde G., et al. ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 2013, 63(1):58-66.
9. Sfakianos J.P., Galsky M.D. Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer. Urol Clin North Am 2015, 42(2):181-187.
10. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507(7492):315-322.
11. Guo G., Sun X., Chen C., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013, 45(12):1459-1463.
12. Iyer G., Al-Ahmadie H., Schultz N., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013, 31(25):3133-3140.
13. Van Allen E.M., Wagle N., Stojanov P., et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014, 20(6):682-688.
14. Frampton G.M., Fichtenholtz A., Otto G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013, 31(11):1023-1031.
15. Sonpavde G., Sternberg C.N., Rosenberg J.E., et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010, 11(9):861-870.
16. Ikeda S., Hansel D.E., Kurzrock R. Beyond conventional chemotherapy: emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. Cancer Treat Rev 2015, 41(8):699-706.
17. Hoadley K.A., Yau C., Wolf D.M., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014, 158(4):929-944.
18. Damrauer J.S., Hoadley K.A., Chism D.D., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014, 111(8):3110-3115.
19. Kurtoglu M., Davarpanah N.N., Qin R., et al. Elevating the horizon: emerging molecular and genomic targets in the treatment of advanced urothelial carcinoma. Clin Genitourin Cancer 2015, 13(5):410-420.
20. McConkey D.J., Choi W., Ochoa A., et al. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am 2015, 29(2):377-394.
21. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22(47):7265-7279.
22. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33(1):9-23.
23. Gossage L., Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007, 33(6):565-577.
24. Bellmunt J., Paz-Ares L., Cuello M., et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007, 18(3):522-528.
25. Allen E.M.V., Mouw K.W., Kim P., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014, 4(10):1140-1153.
26. Ferreira C.G., Tolis C., Giaccone G. p53 and chemosensitivity. Ann Oncol 1999, 10(9):1011-1021.
27. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9(10):749-758.
28. Morris L.G.T., Chan T.A. Therapeutic targeting of tumor suppressor genes. Cancer 2015, 121(9):1357-1368.
29. Leijen S., Beijnen J.H., Schellens J.H. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 2010, 5(3):186-191.
30. Fan S., Smith M.L., Rivert D.J., et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995, 55(8):1649-1654.
31. Fan S., El-Deiry W.S., Bae I., et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994, 54(22):5824-5830.
32. Cote R.J., Esrig D., Groshen S., et al. p53 and treatment of bladder cancer. Nature 1997, 385(6612):123-125.
33. Stadler W.M., Lerner S.P., Groshen S., et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011, 29(25):3443-3449.
34. Iyer G., Hanrahan A.J., Milowsky M.I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338(6104):221.
35. Wagle N., Grabiner B.C., Allen E.M.V., et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014, 4(5):546-553.
36. Sequist L.V., Cassier P., Varga A., et al. Abstract CT326: phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res 2014, 74(19 Suppl):CT326.
37. Dienstmann R., Bahleda R., Adamo B., et al. Abstract CT325: first in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors. Cancer Res 2014, 74(19 Suppl):CT325.
38. Wu Y.-M., Su F., Kalyana-Sundaram S., et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013, 3(6):636-647.
39. Williams S.V., Hurst C.D., Knowles M.A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013, 22(4):795-803.
40. Groenendijk F.H., de Jong J., Fransen van de Putte E.E., et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2015, 10.1016/j.eururo.2015.01.014.
41. Kim J., Fox C., Peng S., et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest 2014, 124(12):5145-5158.
42. Sjödahl G., Lauss M., Lövgren K., et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012, 18(12):3377-3386.
43. Choi W., Porten S., Kim S., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25(2):152-165.
44. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
45. Prat A., Parker J.S., Karginova O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12(5):R68.
46. Esserman L.J., Berry D.A., Cheang M.C.U., et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2011, 132(3):1049-1062.
47. Esserman L.J., Berry D.A., DeMichele A., et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012, 30(26):3242-3249.
48. Santagata S., Thakkar A., Ergonul A., et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest 2014, 124(2):859-870.
49. Kim J.W., Tomita Y., Trepel J., et al. Emerging immunotherapies for bladder cancer. Curr Opin Oncol 2015, 27(3):191-200.
50. Nair S., Boczkowski D., Moeller B., et al. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003, 102(3):964-971.
51. Cohen J.J. Apoptosis: mechanisms of life and death in the immune system. J Allergy Clin Immunol 1999, 103(4):548-554.
52. Senovilla L., Vitale I., Martins I., et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012, 337(6102):1678-1684.
53. Kim R., Emi M., Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007, 121(1):1-14.
54. Askeland E.J., Newton M.R., O'Donnell M.A., et al. Bladder cancer immunotherapy: BCG and beyond. Adv Urol 2012, 2012:181987.
55. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop 1991, (262):3-11.
56. Redelman-Sidi G., Glickman M.S., Bochner B.H. The mechanism of action of BCG therapy for bladder cancer: a current perspective. Nat Rev Urol 2014, 11(3):153-162.
57. Gan C., Mostafid H., Khan M.S., et al. BCG immunotherapy for bladder cancer: the effects of substrain differences. Nat Rev Urol 2013, 10(10):580-588.
58. Herbst R.S., Soria J.-C., Kowanetz M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515(7528):563-567.
59. Xylinas E., Robinson B.D., Kluth L.A., et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol 2014, 40(1):121-127.
60. Nakanishi J., Wada Y., Matsumoto K., et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007, 56(8):1173-1182.
61. Powles T., Eder J.P., Fine G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515(7528):558-562.
62. Huang Y., Zhang S.-D., McCrudden C., et al. The prognostic significance of PD-L1 in bladder cancer. Oncol Rep 2015, 33(6):3075-3084.
63. Parry R.V., Chemnitz J.M., Frauwirth K.A., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005, 25(21):9543-9553.
64. Schindler K., Schicher N., Kunstfeld R., et al. A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody. Melanoma Res 2012, 22(4):320-325.
65. Carthon B.C., Wolchok J.D., Yuan J., et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010, 16(10):2861-2871.
66. Liakou C.I., Kamat A., Tang D.N., et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008, 105(39):14987-14992.
67. Rosenberg S.A., Restifo N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015, 348(6230):62-68.
68. Sherif A., Hasan M.N., Radecka E., et al. Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. Scand J Urol 2015, 1-10.
69. Meric-Bernstam F., Johnson A., Holla V., et al. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 2015, 107(7):djv098.
70. Tsimberidou A.-M., Wen S., Hong D.S., et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res 2014, 20(18):4827-4836.
71. Schilsky R.L. Implementing personalized cancer care. Nat Rev Clin Oncol 2014, 11(7):432-438.
72. McClellan M., Daniel G., Dickson D., et al. Improving evidence developed from population-level experience with targeted agents. Clin Pharmacol Ther 2015, 97(5):478-487.